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Gemcitabine, Cisplatin, and Hyperfractionated Accelerated
Radiotherapy for Locally Advanced Non-small Cell
Lung Cancer
Matjaz Zwitter, PhD, MD, Viljem Kovac, MSc, MD, Uros Smrdel, MD, and Primoz Strojan, PhD, MD
Background: Due to potent radiosensitization and potential serious
or fatal toxicity, concurrent gemcitabine and irradiation should only
be applied within clinical trials. We here present experience from a
phase I-II clinical trial for patients with locally advanced non-small
cell lung cancer (NSCLC) treated with hyperfractionated accelerated
radiotherapy and concurrent low-dose gemcitabine.
Methods: Eligible patients had locally advanced inoperable NSCLC
without pleural effusion, Eastern Cooperative Oncology Group per-
formance status 0-1, were chemotherapy naı¨ve and had no previous
radiotherapy to the chest, and had adequate hematopoietic, liver, and
kidney function. Routine brain computed tomography was not per-
formed, and positron emission tomography/computed tomography
was not available. Treatment consisted of three parts: induction
chemotherapy with gemcitabine and cisplatin in standard doses,
local treatment with concurrent chemotherapy and radiotherapy, and
consolidation chemotherapy. Patients were irradiated with opposed
AP-PA and oblique fields, using 2.5-D treatment planning. Although
corrections for inhomogeneous tissue were made, volume of total
lung receiving 20 Gy (V20) could not be determined. The trial
started as phase I, aimed to determine the dose-limiting toxicity and
maximal tolerated dose (MTD) for concurrent hyperfractionated
radiotherapy (1.4 Gy twice daily) and gemcitabine 55 mg/m2 twice
weekly as a radiosensitizer. Phase II of the trial then continued at the
level of MTD.
Results: Twenty-eight patients with NSCLC, nine patients with
stage IIIA, 16 patients with IIIB, and three patients with an inoper-
able recurrence after previous surgery, entered the trial. The first 12
patients entered Phase I of the trial at the initial level of 42 Gy in 30
fractions in 3 weeks. Dose-limiting toxicity was acute esophagitis;
47.6 Gy in 34 fractions in 3.5 weeks was the MTD for this regimen
of concurrent chemotherapy and radiotherapy. In phase II of the
trial, this dose was applied to the next 16 patients. Among all 28
patients, 13 had grade 3 or 4 acute toxicity: esophagitis (eight
patients), neutropenia (eight patients), thrombocytopenia (four pa-
tients), and anemia (two patients). No pulmonary toxicity and no
persistent or serious late toxicity were seen. Local and/or regional
relapse was documented in nine patients, distant in five and both
locoregional and distant in 10 patients. The most common sites of
distant spread were the brain and lung in eight and six patients,
respectively. At 2 years, progression-free survival was 43% and
overall survival was 57%. After 43 to 85 months of follow-up, seven
patients are alive, of whom six (21%) are without evidence of
disease and may be regarded as long-term survivors. Among the
long-term survivors, one was in the group irradiated to 42 Gy and six
in the groups irradiated to 47.6 Gy.
Conclusion: Judging from current standards, the methods used in
diagnostics and in planning of radiotherapy were suboptimal. Using
modern radiotherapy planning, a higher MTD, possibly a different
profile of toxicity, and better long-term results may be expected. The
high incidence of brain relapse emphasizes the need for careful
screening for unsuspected brain disease before treatment and the
importance of clinical studies on prophylactic cranial irradiation for
patients with locally advanced NSCLC. Although the small number
of patients in this study precludes any definitive conclusion, it
appears that our program of concurrent chemotherapy and radiother-
apy offers a chance for disease control at least comparable to
previously described programs for inoperable lung cancer.
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When approaching a patient with inoperable non-smallcell lung cancer (NSCLC), two problems must be
addressed: the problem of local tumor control and the prob-
lem of distant micrometastases. The standard approach is
combination of chemotherapy and radiotherapy.1,2 When
compared to sequential treatment, concurrent radiotherapy
and chemotherapy are associated with higher toxicity but lead
to superior time to progression and overall survival.3–5
The past decade brought progress in local and in sys-
temic treatment. Regarding local treatment, there is evidence
in favor of hyperfractionated accelerated radiotherapy
(HART), as compared to standard fractionation regimens.6,7
The same trend in favor of HART was reported in a recent
trial of combined chemotherapy and irradiation.8 Regarding
systemic treatment, chemotherapy with the third-generation
of cytotoxic drugs (gemcitabine, taxanes, vinorelbine) in
combination with cisplatin or carboplatin offers higher activ-
ity and often less toxicity when compared to older cisplatin-
based combinations.9–11
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The objective of this trial was to assess toxicity and
efficacy of a novel approach of combined treatment for
locally advanced NSCLC. Treatment program consisted of
induction chemotherapy, local treatment with concurrent hy-
perfractionated accelerated radiotherapy and low-dose gem-
citabine as a radiosensitizer and consolidation chemotherapy.
PATIENTS AND METHODS
Patients
Staging included chest x-ray, computed tomography
(CT) for chest and upper abdomen, bronchoscopy, abdominal
ultrasonography, and bone scintigraphy. In the absence of
neurologic symptoms, brain CT was not performed; positron
emission tomography or positron emission tomography/CT
was not available. Patients eligible for this trial had histologic
or cytologic diagnosis of NSCLC, stage IIIA or IIIB inoper-
able cancer without malignant pleural effusion, Eastern Co-
operative Oncology Group performance status 0-1, were
chemotherapy naı¨ve and had no previous radiotherapy to the
chest, and had adequate hematopoietic, liver, and kidney
function.
All patients were fully informed and consented to
participate in the trial. The trial was approved by the Institu-
tional Protocol Review Board and by the National Committee
for Medical Ethics.
Induction Chemotherapy
Treatment started with two cycles of chemotherapy
with gemcitabine (1250 mg/m2, days 1 and 8) and cisplatin
(70 mg/m2, day 1).
Local treatment
The target volume included the gross tumor and in-
volved lymph nodes with margin of 2 to 3 cm in craniocaudal
and 1 to 1.5 cm in other directions. The dose was prescribed
to the isodose line, which encompassed the target volume;
dose variations of 5% inside this volume were considered
acceptable. Using 2.5 D treatment planning system, correc-
tions were made for tissue inhomogeneities. Patients were
treated on linear accelerator with 5 to 10 MeV x-rays with
AP-PA and one or two opposed oblique fields. The total dose
to the spinal cord was kept under 45 Gy. Due to limitations of
the planning system, volume of total lung receiving 20 Gy or
more (V20) was not determined. Patients underwent irradia-
tion twice daily with 1.4 Gy per fraction to a weekly dose 14
Gy. Phase I of the trial started at 42 Gy in 3 weeks. According
to the plan for dose escalation, first three patients would
receive a total dose of 42 Gy in 3 weeks, after which groups
of six patients would receive a total dose of 47.6 Gy, 50.4 Gy,
53.2 Gy, and 56 Gy in 3.5 to 4 weeks. Our initial plan was to
include 27 patients in Phase I of the trial. After establishing
the maximal tolerated dose (MTD) for the concomitant che-
motherapy/radiotherapy part of the protocol, the trial should
continue as phase II and include a total of 80 patients.
Monitoring for acute toxicity included regular weekly
hematology, biochemistry, body weight, and physical exam-
ination. In the absence of pulmonary symptoms, routine
pulmonary tests were not performed. The MTD was defined
as the radiation dose level at one cohort below that, which
resulted in more than 33% of patients experiencing any grade
3 or greater acute toxicity.
During radiotherapy, gemcitabine at a dose of 55
mg/m2 was given twice weekly.
Consolidation Chemotherapy
After an interval of 2 to 3 weeks, patients continued
with two to four cycles of systemic treatment with gemcit-
abine and cisplatin in the same doses as during induction
chemotherapy.
RESULTS
From February 1999 to November 2002, 28 patients
(19 men, nine women, age 33 to 72 years, median age 52
years) entered the trial. Histology was squamous in 14 pa-
tients, adenocarcinoma in nine patients, and large cell or
poorly differentiated in five patients. The stage were IIIA
(nine patients), IIIB (16 patients, of whom two had superior
vena cava syndrome), and inoperable recurrence after previ-
ous surgery (three patients).
Induction Chemotherapy
No grade 3 toxicity from the induction chemotherapy
was recorded.
Of 21 patients who were assessable for response, there
were no complete responses, 12 partial remissions, and nine
minimal responses or stable disease.
Local Treatment
The first 12 patients entered Phase I of the trial and
were treated with escalating total doses of irradiation: 42 Gy
in 3 weeks (three patients), 47.6 Gy in 3.5 weeks (six
patients), and 50.4 Gy in 4 weeks (three patients). All three
patients irradiated to 50.4 Gy had grade 3 acute toxicity:
esophagitis in two patients (one of whom also had grade 3
neutropenia) and thrombocytopenia in one. Based on this
admittedly limited experience, acute esophagitis was defined
as the dose-limiting toxicity. Subsequent 16 patients were
treated as Phase II of the trial to 47.6 Gy as our estimate of
the maximal tolerated dose.
An overview of acute toxicity is presented in Table 1.
In nine patients, some applications of gemcitabine as a
radiosensitizer had to be omitted due to hematologic toxicity,
general malaise, and/or nausea. Based on a plan to combine
irradiation with twice-weekly low-dose gemcitabine, on av-
erage 94% (range 40%–100%) of radiotherapy was actually
covered by gemcitabine.
Most patients experienced general malaise and nausea
(grade 2, 20 patients). Grade 2 and 3 esophagitis was present
in 14 and eight patients, respectively. Median loss of body
weight was 3 kg (range 0–12 kg) or 5% (range 0%–15%) of
body weight. After a median interval of 10 days (range 6–25
days) from the end of radiotherapy, patients could eat nor-
mally and were again gaining weight. No lasting conse-
quences of esophagitis were seen.
Anemia (grades 2 and 3 in 16 and two patients, respec-
tively) was common, with mean hemoglobin nadir at 94 g/L.
Grade 2, 3, and 4 neutropenia occurred in 14, five, and three
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patients, with one case of febrile neutropenia. Grade 2, 3, and
4 thrombocytopenia was seen in six, two, and two patients,
respectively. In all cases, neutrophil and platelet counts re-
turned to normal within 13 days.
One patient died 3 weeks after radiotherapy. A 71-year-
old man with a recurrence of lung cancer after surgery and
destruction of the vertebral body suffered ventricular fibril-
lation and heart arrest. The relationship between the treatment
and the fatal outcome remains unclear.
Consolidation Chemotherapy
No grade 3 toxicity was seen during consolidation
chemotherapy.
Long-term toxicity
Eight months after completing treatment with 42 Gy as
the total dose to the spinal cord, one patient developed
transient paraparesis of the lower limbs. Myelography and
magnetic resonance imaging were negative for tumor inva-
sion. After treatment with corticosteroids, the symptoms
resolved and did not recur in the next 3 years. No other late
toxicity was seen.
Disease progression and survival
No patient was lost to follow-up. The median follow-up
for patients alive at close-out date (March 1, 2006) was 60
months (range 43–85 months).
Among all 28 patients who entered the trial, seven
patients are alive, six (21%) of whom are currently without
evidence of disease and may be regarded as long-term sur-
vivors. In addition to four patients who never had a relapse,
two had surgery and radiotherapy for brain metastases and are
without evidence of disease 28 and 47 months later, respec-
tively. Among the long-term survivors, one was in the group
irradiated to 42 Gy and six in the groups irradiated to 47.6
Gy. Local and/or regional relapse was documented in nine
patients, distant in five, and both locoregional and distant in
10 patients. The most common sites of distant spread were
the brain and lung in eight and six patients, respectively.
Median time to progression and survival were 16 and
28 months, respectively. At 2 years, progression-free survival
was 43% (95% CI: 25 – 61%) and overall survival was 57%
(95% CI: 39 – 75%). At 3 years, progression-free survival
was 18% (95% CI: 4 – 32%) and overall survival was 43%
(95% confidence interval: 25%–61%) (Figure 1).
DISCUSSION
The objective of this trial was to explore the feasibility
of a novel approach of combined treatment with gemcitabine
and cisplatin and radiotherapy in locally advanced NSCLC.
Our induction and consolidation chemotherapy followed the
standard schedule used in many other trials of locally ad-
vanced or metastatic NSCLC. The innovative part of the
protocol was the local treatment with hyperfractionated ac-
celerated radiotherapy and concurrent gemcitabine as a ra-
diosensitizer. We start the discussion with an explanation of
the design of this part of the treatment protocol. Comments
on actual performance of the trial and on our experience are
then presented.
Early experience with radiotherapy and concurrent
gemcitabine revealed serious and even fatal toxicity. It is now
clear that both modalities in full doses cannot be used
simultaneously.12–14 Further laboratory and clinical studies
confirmed potent radiosensitizing properties of gemcitab-
ine.15,16 Radiosensitization is seen even at very low doses of
approximately 35 to 60 mg/m2 and last for as long as 72
hours, much longer than the short-lived effect of the older
sensitizers such as cisplatin. In routine clinical practice,
simultaneous use of gemcitabine and irradiation should be
avoided and a 2-week gap between the two modalities is
recommended. However, in clinical research, several phase
I/II trials were developed to test the potential clinical benefit
of a carefully designed combined treatment for patients with
inoperable cancers of the lung, pancreas, head and neck,
cervix, or bladder. When used as a radiosensitizer, gemcitab-
ine is given either once weekly at 300 to 1000 mg/m2 or twice
weekly at a single dose of 40 to 60 mg/m2.17–23
In our trial, gemcitabine at 55 mg/m2 was given twice
weekly to cover the whole week of radiotherapy. Unconven-
tional fractionation of irradiation was chosen since we pre-
ferred acute (and usually reversible) rather than late (and
often irreversible) dose-limiting toxicity of the concurrent
gemcitabine/radiotherapy. With the standard 2 Gy per frac-
tion and considering the factor of radiosensitization of gem-
citabine, the biologic dose per fraction would be approxi-
TABLE 1. Number of patients with grade 2, 3, or 4 toxicity
Phase I Phase II All
Dose level (Gy) 42 47.6 50.4 47.6 42–50.4
No. of patients 3 6 3 16 28
Esophagitis Grade 2 2 5 7 14
Grade 3 1 1 2 4 8
Anemia Grade 2 2 4 3 7 16
Grade 3 2 2
Neutropenia Grade 2 1 1 2 10 14
Grade 3 1 1 1 2 5
Grade 4 1 2 3
Thrombocytopenia Grade 2 1 5 6
Grade 3 1 1 2 2 6
Grade 4 2 2
Any grade 3 or 4 toxicity 2 2 3 6 13
Due to a small number of patients in each group, percentages are not presented.
FIGURE 1. Progression-free survival and overall survival.
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mately 3 Gy and the risk of late toxicity substantially
increased. Twice-daily fractionation was chosen to avoid a
very prolonged course of irradiation, a factor that may lead to
poor survival.24
Our primary aim was to define the MTD and the
dose-limiting toxicity for a regimen of concurrent hyperfrac-
tionated irradiation and low-dose gemcitabine. Our estimate
is that 47.6 Gy in 34 fractions in 17 treatment days is the dose
that most patients can tolerate and that will not lead to serious
late toxicity. This dose is biologically equivalent to 46 Gy
delivered in 23 daily fractions of 2 Gy over 31 days (standard
fractionation; calculation on biologic equivalence based on
/  10 Gy). Thus, the total dose in our trial is 77% of the
standard regimen of 60 Gy in 30 fractions in 6 weeks. The
reduction of the MTD in our trial corresponds to 1.3 as the
factor of radiosensitization due to concurrent gemcitabine, a
figure that compares well with the published data on gemcit-
abine-enhanced radiosensitivity.25,26
A detailed look at the actual performance of our trial
reveals four areas of criticism and, at the same time, of
potential for improvement of results: staging, radiotherapy
planning, attention to anemia, and small sample.
There is little doubt that PET/CT, not available to the
patients in our trial, would detect clinically silent distant
spread in a substantial proportion of patients. When dealing
with apparently locally advanced disease, careful staging is
essential to select only those patients for whom a potentially
curative treatment with significant acute toxicity is justified.
Judging from the present standards, the radiotherapy
part of the treatment was suboptimal. Dose calculations and
therapy planning were done without three-dimensional CT-
assisted treatment planning. These factors contributed to dose
inhomogeneity and, consequently, to more pronounced treat-
ment-related side effects and suboptimal tumor control. Most
of the dose was delivered through opposed AP-PA fields, an
approach that explains a high incidence of acute esophagitis
and possibly also absence of pulmonary toxicity in our trial.
With modern treatment planning, we could expect a higher
MTD, possibly a different profile of side effects, and im-
proved tumor control.27,28
Anemia is the third area for potential improvement of
our results. Mean hemoglobin levels were 116 g/L after
induction chemotherapy and 93 g/L at the nadir during
concurrent chemotherapy/radiotherapy. Anemia lowers radi-
osensitivity and is a well-recognized prognostic factor for
tumor control after radical radiotherapy.29,30 We would ex-
pect that correction of anemia before radiotherapy would
further improve long-term results.
The fourth obvious weak point of our trial is the small
number of patients. In December 2002, accrual to the trial
closed prematurely. The decision was made after serious
technical problems on two linear accelerators led to tempo-
rary substantial limitations in the access to radiotherapy in
Slovenia. In 2004–2006, a modern system for treatment
planning and four new accelerators were installed; an addi-
tional new unit is expected within the next eight months.
Although we can now offer new modern facilities for routine
treatment and for clinical research, a gap of 4 years was
considered too long to reopen accrual to this particular trial.
We believe that experience with this small group of patients
deserves to be presented, and a new trial will test this
approach using new technology.
As local and systemic treatment for NSCLC improves,
the risk of brain metastases increases. In our series, eight
patients (29 %) developed brain metastases as the most
frequent site of distant spread. Two recommendations follow.
First, screening for clinically silent brain metastases should
be a routine part of staging before intensive chemotherapy/
radiotherapy for locally advanced lung cancer.31 Second,
prophylactic cranial radiotherapy should be considered for
patients in remission. This emphasizes the importance of the
ongoing Radiation Therapy Oncology Group 0214 trial of
prophylactic cranial radiotherapy in stage III NSCLC.
Our trial offers a new and hitherto unreported approach
to the treatment of inoperable NSCLC. The acute side effect
of grade 3 esophagitis was common but transient, and no
severe late toxicity was seen. Overall survival at 2 and 3 years
was 57% and 42%, respectively; six patients (21%) may be
regarded as long-term survivors. Although the small number
of patients precludes any definitive conclusion, it appears that
our program of concurrent chemotherapy/radiotherapy offers
a chance for disease control at least comparable to that in
previously described programs for inoperable lung cancer.
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